[Clinical Characteristics and Prognosis of B-cell Acute Lymphoblastic Leukemia Patients with IKZF1 Deletion].

Q4 Medicine

中国实验血液学杂志 Pub Date : 2025-08-01 DOI:10.19746/j.cnki.issn.1009-2137.2025.04.006

Li-Hua Wang, Yan Guo, Yuan Zhang, Xiu-Feng Wang, Xian-Kai Liu, Yan Huang

{"title":"[Clinical Characteristics and Prognosis of B-cell Acute Lymphoblastic Leukemia Patients with IKZF1 Deletion].","authors":"Li-Hua Wang, Yan Guo, Yuan Zhang, Xiu-Feng Wang, Xian-Kai Liu, Yan Huang","doi":"10.19746/j.cnki.issn.1009-2137.2025.04.006","DOIUrl":null,"url":null,"abstract":"Objective: To analyze clinical characteristics and prognosis of B-cell acute lymphoblastic leukemia (B-ALL) patients with IKZF1 deletion.Methods: 72 patients with B-ALL admitted to our hospital from April 2020 to January 2023 were selected, IKZF1 deletion were detected, and clinical characteristics and prognosis were analyzed.Results: Among the 72 patients, a total of 32 patients (44.4%) were identified with IKZF1 deletions (IKZF1 + ). There was no statistically significant difference in basic clinical data between patients with normal IKZF1 (IKZF1 -) and those with IKZF1 + (P >0.05). The proportion of patients with IKZF1 + in Ph+ group was significantly higher than that in Ph- group (P < 0.05). The main types of IKZF1 + were exon 1-8 deletion (34.4%) and exon 4-7 deletion (31.2%). The median OS and PFS of IKZF1 - patients were significantly longer than those of IKZF1 + patients (OS: 26.0 months vs 16.0 months, χ 2=23.094, P < 0.05; PFS: 26.0 months vs 16.0 months, χ 2=11.150, P < 0.05). Among IKZF1 + patients, the median OS of patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) was significantly longer than that of patients who did not receive allo-HSCT (no reached vs 15.0 months, χ 2=5.685, P < 0.05).Conclusion: IKZF1 deletion is a risk factor affecting the prognosis of B-ALL patients.","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"33 4","pages":"966-971"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国实验血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.19746/j.cnki.issn.1009-2137.2025.04.006","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To analyze clinical characteristics and prognosis of B-cell acute lymphoblastic leukemia (B-ALL) patients with IKZF1 deletion.

Methods: 72 patients with B-ALL admitted to our hospital from April 2020 to January 2023 were selected, IKZF1 deletion were detected, and clinical characteristics and prognosis were analyzed.

Results: Among the 72 patients, a total of 32 patients (44.4%) were identified with IKZF1 deletions (IKZF1 ⁺ ). There was no statistically significant difference in basic clinical data between patients with normal IKZF1 (IKZF1 ^-) and those with IKZF1 ⁺ (P >0.05). The proportion of patients with IKZF1 ⁺ in Ph⁺ group was significantly higher than that in Ph^- group (P < 0.05). The main types of IKZF1 ⁺ were exon 1-8 deletion (34.4%) and exon 4-7 deletion (31.2%). The median OS and PFS of IKZF1 ^- patients were significantly longer than those of IKZF1 ⁺ patients (OS: 26.0 months vs 16.0 months, χ ²=23.094, P < 0.05; PFS: 26.0 months vs 16.0 months, χ ²=11.150, P < 0.05). Among IKZF1 ⁺ patients, the median OS of patients who received allogeneic hematopoietic stem cell transplantation (allo-HSCT) was significantly longer than that of patients who did not receive allo-HSCT (no reached vs 15.0 months, χ ²=5.685, P < 0.05).

Conclusion: IKZF1 deletion is a risk factor affecting the prognosis of B-ALL patients.

查看原文本刊更多论文

[IKZF1基因缺失b细胞急性淋巴细胞白血病患者的临床特点及预后分析]。

目的：分析IKZF1基因缺失的b细胞急性淋巴细胞白血病（B-ALL）患者的临床特点及预后。方法：选取2020年4月~ 2023年1月我院收治的B-ALL患者72例，检测IKZF1基因缺失，分析其临床特征及预后。结果：72例患者中，共有32例（44.4%）患者被鉴定为IKZF1缺失（IKZF1 +）。IKZF1正常（IKZF1 -）与IKZF1 +患者的基本临床资料比较，差异无统计学意义（P < 0.05）。Ph+组IKZF1 +患者比例显著高于Ph-组（P < 0.05）。IKZF1 +的主要类型为外显子1-8缺失（34.4%）和外显子4-7缺失（31.2%）。IKZF1 -组患者的中位OS和PFS均明显长于IKZF1 +组（OS: 26.0个月vs 16.0个月，χ 2=23.094, P < 0.05; PFS: 26.0个月vs 16.0个月，χ 2=11.150, P < 0.05）。在IKZF1 +患者中，接受同种异体造血干细胞移植（allogeneic hematopoietic stem cell transplantation, alloo - hsct）的患者的中位生存期明显长于未接受同种异体造血干细胞移植的患者（no达到vs 15.0个月，χ 2=5.685, P < 0.05）。结论：IKZF1基因缺失是影响B-ALL患者预后的危险因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊